142 related articles for article (PubMed ID: 8159252)
1. [Definitive end-stage chronic kidney failure after cisplatin treatment].
Brillet G; Deray G; Lucsko M; Faucher C; Aubert P; Rottembourg J; Jacobs C
Nephrologie; 1993; 14(5):227-9. PubMed ID: 8159252
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin nephrotoxicity: experimental and clinical studies.
Daugaard G
Dan Med Bull; 1990 Feb; 37(1):1-12. PubMed ID: 2178884
[TBL] [Abstract][Full Text] [Related]
3. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
4. [Squamous cell carcinoma of the lung detected during maintenance hemodialysis which reduced in size after combined CDDP chemotherapy].
Umeki S; Wakunami M; Kawane H; Soegima R
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Sep; 28(9):1225-9. PubMed ID: 2266629
[TBL] [Abstract][Full Text] [Related]
5. [Combined 5-FU and CDDP in a gastric cancer patient undergoing hemodialysis--pharmacokinetics of 5-FU and CDDP].
Cho H; Imada T; Masudo K; Doi C; Inaba M; Tokunaga M; Takanashi Y
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2135-8. PubMed ID: 11103248
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy].
Tokunaga J; Kikukawa H; Nishi K; Kitani K; Fujii J; Honda J; Wada Y; Ueda S; Nakano M
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2079-85. PubMed ID: 11103239
[TBL] [Abstract][Full Text] [Related]
7. [M-VAC therapy in a patient with ureteral carcinoma accompanied by chronic renal failure].
Yokogi H; Yamasaki Y; Ishibe T
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2405-7. PubMed ID: 8259861
[TBL] [Abstract][Full Text] [Related]
8. [Change of creatinine clearance rate in accordance with aging in Japanese patients with head and neck cancer].
Nishimura G; Horiuchi C; Yoshida T; Kawakami M; Yabuki K; Taguchi T; Nagao J; Kondo N; Masuda Y; Matsuda H; Mikami Y; Tsukuda M
Gan To Kagaku Ryoho; 2006 Apr; 33(4):463-6. PubMed ID: 16612154
[TBL] [Abstract][Full Text] [Related]
9. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
10. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
11. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
12. Effects of nifedipine on cisplatinum-induced nephrotoxicity in rats.
Deray G; Dubois M; Beaufils H; Cacoub P; Anouar M; Jaudon MC; Baumelou A; Jouanneau C; Jacobs C
Clin Nephrol; 1988 Sep; 30(3):146-50. PubMed ID: 3180522
[TBL] [Abstract][Full Text] [Related]
13. [Cisplatin administration for outpatients with short hydration of less than four hours].
Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
16. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
17. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug].
Okuyama M; Motoyama S; Maruyama K; Ohta H; Tsuchiya N; Oyake J; Ogawa J
Gan To Kagaku Ryoho; 2005 Jul; 32(7):1029-32. PubMed ID: 16044967
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues.
Aleisa AM; Al-Majed AA; Al-Yahya AA; Al-Rejaie SS; Bakheet SA; Al-Shabanah OA; Sayed-Ahmed MM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1252-9. PubMed ID: 17973863
[TBL] [Abstract][Full Text] [Related]
20. [Study on changes in plasma platinum concentrations after administration of CDDP to maintenance hemodialysis patients].
Suwata J; Hiraga S; Hida M; Takamiya T; Iida T; Sato T
Gan To Kagaku Ryoho; 1988 Feb; 15(2):243-8. PubMed ID: 3341786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
